|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100049636 |
|
最近更新日期: Date of Last Refreshed on: |
2022-03-08 19:59:32 |
|
注册时间: Date of Registration: |
2021-08-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
胚胎移植第12天HCG,PlGF和sFlt1联合预测大产科综合征的临床研究 |
|
Public title: |
Clinical study of combined prediction of HCG, PlGF and sFlt1 on day 12 of embryo transfer in predicting large obstetric syndrome |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
胚胎移植第12天HCG,PlGF和sFlt1联合预测大产科综合征的临床研究 |
|
Scientific title: |
Clinical study of combined prediction of HCG, PlGF and sFlt1 on day 12 of embryo transfer in predicting large obstetric syndrome |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张琼 |
研究负责人: |
张琼 |
|
Applicant: |
Zhang Qiong |
Study leader: |
Zhang Qiong |
|
申请注册联系人电话: Applicant telephone: |
+86 13787224913 |
研究负责人电话: Study leader's telephone: |
+86 13787224913 |
|
申请注册联系人传真 : Applicant Fax: |
+86 731 84327332 |
研究负责人传真: Study leader's fax: |
+86 731 84327332 |
|
申请注册联系人电子邮件: Applicant E-mail: |
zhangqiong1997@yahoo.com |
研究负责人电子邮件: Study leader's E-mail: |
zhangqiong1997@yahoo.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省长沙市开福区湘雅路87号 |
研究负责人通讯地址: |
湖南省长沙市开福区湘雅路87号 |
|
Applicant address: |
87 Xiangya Road, Kaifu District, Changsha, Hu'nan |
Study leader's address: |
87 Xiangya Road, Kaifu District, Changsha, Hu'nan |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中南大学湘雅医院 |
||
|
Applicant's institution: |
Xiangya Hospital, Central South University |
||
|
研究负责人所在单位: |
中南大学湘雅医院 |
||
|
Affiliation of the Leader: |
Xiangya Hospital, Central South University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2021018 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中南大学湘雅医院生殖医学伦理委员会 |
||
|
Name of the ethic committee: |
Reproductive medicine ethics committee of Xiangya Hospital, Central South University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-08-04 00:00:00 |
||
|
伦理委员会联系人: |
李玉梅 |
||
|
Contact Name of the ethic committee: |
Li Yumei |
||
|
伦理委员会联系地址: |
湖南省长沙市开福区湘雅路87号 |
||
|
Contact Address of the ethic committee: |
87 Xiangya Road, Kaifu District, Changsha, Hu'nan |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
中南大学湘雅医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Xiangya Hospital, Central South University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省长沙市开福区湘雅路87号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
87 Xiangya Road, Kaifu District, Changsha, Hu'nan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
湖南省卫健委科研计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Research Plan of Hu'nan National Health Commission |
||||||||||||||||||||||
|
Target disease: |
Great Obstetrical Syndromes |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
诊断试验新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
Diagnostic New Technique Clincal Study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
检测胚胎移植第12天外周血HCG,PlGF和sFlt1水平,评价胚胎着床期合体滋养细胞和细胞滋养细胞的功能,评估子宫螺旋动脉重铸情况,统计分析以获得预测大产科综合征疾病的风险值,为更早的预测,监测,防治大产科综合征提供参考。 |
||||||||||||||||||||||
|
Objectives of Study: |
The levels of HCG, PlGF and sFlt1 in peripheral blood were detected on the 12th day of embryo transfer, and the functions of syncytiotrophoblasts and cytotrophoblasts during embryo implantation were evaluated. Evaluate the remodeling of uterine spiral artery, and make statistical analysis to obtain the risk value for predicting the disease of large obstetric syndrome, and provide a reference for earlier prediction, monitoring, and prevention and treatment of large obstetric syndrome. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
经辅助生殖技术治疗受孕的患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Patients who have been treated with assisted reproductive technology to conceive. |
||||||||||||||||||||||
|
排除标准: |
不愿意进入该项观察性研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients who refuse to be recruited in the observation study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-08-09 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2021-08-09 00:00:00 至 To 2023-02-28 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
该实验为观察性试验,不随机分组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
It is a observation study, participants will not be randomized divided into groups |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2026年12月23日 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
raw data will be opened on 23rd, December, 2026 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
纸质的病例报告表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
case record form in paper version |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |